Results 81 to 90 of about 766 (168)

TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Hematological Oncology, Volume 43, Issue 4, July 2025.
ABSTRACT TP53‐mutated acute myeloid leukemia (AML) remains one of the most treatment‐resistant hematologic malignancies, with poor overall survival despite advancements in therapeutic strategies. The loss of functional p53 compromises DNA repair, apoptosis, and genomic stability, rendering both conventional and novel therapies largely ineffective. This
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +11 more
wiley   +1 more source

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

, 2021
Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are two distinct blood cancers with a variable clinical symptom burden and risk of progression to acute myeloid leukemia.
Amer M. Zeidan, Jan Philipp Bewersdorf
core   +1 more source

AML-1127: TRILLIUM: A Phase 2 Multicenter Trial of Tagraxofusp Plus Venetoclax and Azacitidine (VEN/AZA) in Patients Ineligible for Intensive Chemotherapy (IC) With Previously Untreated CD123+ Acute Myeloid Leukemia (AML)

In AML, VEN/AZA is the standard of care for patients unfit for or refusing IC (complete remission [CR], 36.7%; median overall survival [mOS], 14.7 months).
Gupta, Ira, Pemmaraju, Naveen, Sekeres, Mikkael A., Lane, Andrew A., Kantarjian, Hagop M., Daver, Naval G., Fathi, Amir, Garzon, Jessica, Tosolini, Alessandra   +8 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan malignancy defined by the WHO as affection fewer than 65 per 100,000 people and by the U.S. FDA as affecting less than 200,000 people in the U.S..
Attardi, Enrico, Voskanyan, Astghik, Alencar, Alvaro J, Peng, Ching-Tien, Ohannessian, Robin, Konopleva, Marina, Tamamyan, Gevorg, Martelli, Maria Paola, Mehra, Shefali, Bedirian, Karen, Martirosyan, Nare, Komrokji, Rami S., Abramashvili, Mariam, Kotoucek, Pavel P, Ivanyan, Arusyak, Kutluk, Tezer, Tuğcu, Deniz, Papyan, Ruzanna, Alhuraiji, Ahmad, Tekkesin, Funda, Taylor, Justin, Al-Jadiry, Mazin Faisal, Ghali, Hasanein, Voso, Maria Teresa, Su, Min-Yu, Al Ali, Najla H., Badikyan, Maria, Stancioaica, Maria Camelia, Hovsepyan, Shushan, El-Ashwah, Shaimaa, Danelyan, Samvel, Owen, Carolyn, Ghahramanyan, Nerses, Bakhshi, Sameer, Maghaqyan, Hasmik, Kebudi, Rejin, Pemmaraju, Naveen, Bardakhchyan, Samvel, Sergi, Consolato M, Elashwah, Salma, Kazandjian, Dickran, Coriu, Daniel, Totogashvili, Nino   +42 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm in the Era of Targeted Therapies

Hemato
Blastic plasmocytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, characterized by the involvement of multiple organs, including the skin, bone marrow and blood, lymph nodes and the central nervous system.
Ugo Testa
doaj   +1 more source

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor out-comes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN
Gupta, Vikas, Hagop Kantarjian, Bhatt, Vijaya Raj, Strickland, Stephen, Dhakal, Prajwal, Alice Mims, Andrew A. Lane, Vijaya Raj Bhatt, Lopez-Santiago, Norma, Martin Tallman, Walter, Roland B., Gojo, Ivana, Roboz, Gail J., Matthew J. Wieduwilt, Duvic, Madeleine, Mesa, Ruben, Madeleine Duvic, Vachhani, Pankit, Kharfan-Dabaja, Mohamed A, Hall, Aric Cameron, Stephen Strickland, Fathi, Amir T., Walter, Roland B, Kendra Sweet, Paul Shami, Stein, Anthony S., Wieduwilt, Matthew J, James Mason, Sweet, Kendra, Lancet, Jeffrey, Ivana Gojo, Konopleva, Marina, Marcos de Lima, Guzman, Monica, Aung, Phyu P, Ulrickson, Matthew, Jeffrey Lancet, Edward Gorak, Wang, Eunice, Daver, Naval, Roboz, Gail J, Jacoby, Meagan A, Amir T. Fathi, Tulin Budak-Alpdogan, James Foran, Sumithira Vasu, Monica Guzman, Vasu, Sumithira, Aung, Phyu P., Rampal, Raajit K., Senapati, Jayastu, Frankel, Arthur E., Pankit Vachhani, Eunice Wang, Gorak, Edward, de Lima, Marcos, Pawlowska, Anna, Arthur E. Frankel, Sumeet Bhatia, Budak-Alpdogan, Tulin, Perl, Alexander, Wieduwilt, Matthew J., Marina Konopleva, Lane, Andrew A, Ravandi, Farhad, Naveen Pemmaraju, Justin Taylor, Joseph Khoury, Qazilbash, Muzaffar, Stein, Anthony S, Dale Bixby, Rizzieri, David, Muzaffar Qazilbash, Richard M. Stone, Schiller, Gary, Tallman, Martin, Mohamed A. Kharfan-Dabaja, Mannis, Gabriel, Vikas Gupta, Yazan Madanat, Foran, James, Madanat, Yazan, Gary Schiller, Wilson, Nathaniel R., Matthew Ulrickson, Branko Cuglievan, Lane, Andrew A., Nathaniel R. Wilson, Ruben Mesa, Norma Lopez-Santiago, Lee, Sangmin, Gail J. Roboz, Khoury, Joseph, Naval Daver, Anthony S. Stein, Cuglievan, Branko, Frankel, Arthur E, Jayastu Senapati, Rebecca Olin, Olin, Rebecca, Phyu P. Aung, Shami, Paul, Mason, James, Raajit K. Rampal, Garcia-Romero, Maria Teresa, Stone, Richard M., Fathi, Amir T, Maria Teresa Garcia-Romero, David Rizzieri, Jacoby, Meagan A., Mims, Alice, Sangmin Lee, Taylor, Justin, William Blum, Rampal, Raajit K, Bixby, Dale, Meagan A. Jacoby, Aric Cameron Hall, Bhatia, Sumeet, Kantarjian, Hagop, Gabriel Mannis, Prajwal Dhakal, Alexander Perl, Pemmaraju, Naveen, Roland B. Walter, Gabriela Cesarman-Maus, Farhad Ravandi, Cesarman-Maus, Gabriela, Anna Pawlowska, Wilson, Nathaniel R, Blum, William, Stone, Richard M, Kharfan-Dabaja, Mohamed A.   +132 more
core   +1 more source

NEOPLASIA DE CÉLULAS DENDRÍTICAS PLASMOCITÓIDES COMO DIAGNÓSTICO DIFERENCIAL DE LESÕES CUTÂNEAS EM PACIENTES PEDIÁTRICOS

Hematology, Transfusion and Cell Therapy
Objetivos: Descrever a experiência e desafio diagnóstico de dois pacientes pediátricos com neoplasia de células dendríticas plasmocitóides com apresentação clínica de lesões cutâneas.
GPG Spohr, GM Altizani, AKF Costa, ET Valera, ALM Leite, DP Leal, MBF Reis   +6 more
doaj   +1 more source

Evaluation of targeted therapies for the management of hematological malignancies involving plasmocytoid dendritic cells

, 2022
Les hémopathies impliquant des pDC (BPDCN et LAM-pDC) sont des entités récemment décrites et présentant un pronostic défavorable. Elles sont rares et ne présentent actuellement aucun consensus de traitement.
Poussard, Margaux
core  

Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission

Hematology/Oncology and Stem Cell Therapy
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic disorder derived from precursors of plasmacytoid dendritic cells, with a generally aggressive clinical course.
Mohamed A. Kharfan-Dabaja
doaj   +1 more source

Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: “First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level”

Haematologica
Not available.
Shigeru Kusumoto, Takayoshi Tachibana
doaj   +1 more source